Similar articles

• Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.

  Sakamaki Y, Sasamura H, Ikeda S, Ikegami N, Saruta T. Sakamaki Y, et al. Hypertens Res. 2006 May;29(5):333-8. doi: 10.1291/hypres.29.333. Hypertens Res. 2006. PMID: 16832153
• [German Hypertension League update. What does the ALLHAT Study really mean?].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2003 Jun 5;145(23):45-6. MMW Fortschr Med. 2003. PMID: 12854226 German. No abstract available.
• [Added organ protection at little cost. Double savings with ACE inhibitors].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2003 Nov 27;145(48):63. MMW Fortschr Med. 2003. PMID: 14725008 German. No abstract available.
• [Fully possible to reduce the costs of hypertension treatment].

  Wettermark B, Angman A, Hjemdahl P. Wettermark B, et al. Lakartidningen. 2009 Jun 3-9;106(23):1558-62. Lakartidningen. 2009. PMID: 19583013 Review. Swedish. No abstract available.
• Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.

  Probstfield J. Probstfield J. J Fam Pract. 2009 Jun;58(6 Suppl):S1-8. J Fam Pract. 2009. PMID: 19508849 Review. No abstract available.